Media coverage about Celgene (NASDAQ:CELG) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celgene earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.3913898194111 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Zacks Investment Research Downgrades Celgene (CELG) to Sell (americanbankingnews.com)
- Celgene (CELG) Given “Buy” Rating at Leerink Swann (americanbankingnews.com)
- Celgene’s (CELG) Buy Rating Reiterated at BMO Capital Markets (americanbankingnews.com)
- Celgene (CELG) Cut to “Buy” at Vetr (americanbankingnews.com)
- Global Mitogen Activated Protein Kinase 8 Market 2017 – Celgene Corp, Eisai Co Ltd, OPKO Health Inc – The Daily Telescope (dailytelescope.com)
Celgene (CELG) traded up $0.54 during trading on Tuesday, hitting $106.87. 1,990,328 shares of the stock traded hands, compared to its average volume of 4,833,915. The company has a market capitalization of $83,720.00, a PE ratio of 25.21, a P/E/G ratio of 0.82 and a beta of 1.77. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.
CELG has been the topic of a number of research analyst reports. Morgan Stanley downgraded Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research note on Thursday, October 5th. BTIG Research restated a “hold” rating on shares of Celgene in a research note on Sunday, October 22nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $112.00 price objective on shares of Celgene in a research note on Monday, October 30th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a research note on Monday, October 23rd. Finally, Oppenheimer set a $166.00 price objective on Celgene and gave the company a “buy” rating in a research note on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $134.92.
WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/12/26/celgene-celg-receives-daily-media-sentiment-score-of-0-18-2.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene and related companies.